Inventor · disambiguated record
Solomon Langermann
Also filed as: LANGERMANN SOLOMON
18 granted patents·25 pending applications·1,255 citations·filing 1999–2024
95Inventor score
Top patents by PatentIndex Score
43 records- 0198US8609089B2Compositions of PD-1 antagonists and methods of useLANGERMANN SOLOMON·Filed 2011·Granted Dec 17, 2013·572 cites·23 claims
- 0298US8114845B2Compositions of PD-1 antagonists and methods of useLANGERMANN SOLOMON·Filed 2009·Granted Feb 14, 2012·153 cites·29 claims
- 0397US9205148B2Antibodies and other molecules that bind B7-H1 and PD-1LANGERMANN SOLOMON·Filed 2012·Granted Dec 8, 2015·243 cites·22 claims
- 0497US8709416B2Compositions of PD-1 antagonists and methods of useLANGERMANN SOLOMON·Filed 2011·Granted Apr 29, 2014·102 cites·28 claims
- 0595US9574000B2Anti-human B7-H4 antibodies and their usesMEDIMMUNE LLC·Filed 2013·Granted Feb 21, 2017·62 cites·15 claims
- 0690US9005616B2Methods and compositions for the inhibition of transplant rejectionLANGERMANN SOLOMON·Filed 2010·Granted Apr 14, 2015·13 cites·40 claims
- 0786US9676854B2Anti-B7-H4 antibodies and their usesLIU LINDA·Filed 2012·Granted Jun 13, 2017·17 cites·24 claims
- 0884US9011853B2B7-H4 fusion proteins and methods of use thereofLANGERMANN SOLOMON·Filed 2010·Granted Apr 21, 2015·8 cites·43 claims
- 0983US9957312B2B7-H4 fusion proteins and methods of use thereofMEDIMMUNE LLC·Filed 2015·Granted May 1, 2018·4 cites·54 claims
- 1083US6368599B1Caulobacter LPS immunoadjuvantsUNIV BRITISH COLUMBIA·Filed 2000·Granted Apr 9, 2002·17 cites·7 claims
- 1178US10316092B2Anti-B7-H5 antibodies and their usesMEDIMMUNE LLC·Filed 2014·Granted Jun 11, 2019·3 cites·12 claims
- 1278US6737063B2FimH adhesin proteins and methods of useMEDIMMUNE INC·Filed 2001·Granted May 18, 2004·23 cites·4 claims
- 1377US11390675B2Antibodies for Siglec-15 and methods of use thereofNEXTCURE INC·Filed 2017·Granted Jul 19, 2022·2 cites·3 claims
- 1476US2011159023A1Pd-1 antagonists and methods for treating infectious diseaseLANGERMANN SOLOMON·Filed 2009·Application pending·0 cites
- 1573US6913750B2Therapeutic compounds structurally-linked to bacterial polypeptidesUNIV WASHINGTON·Filed 2001·Granted Jul 5, 2005·9 cites·25 claims
- 1669US6500434B1Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infectionsMEDIMMUNE INC·Filed 1999·Granted Dec 31, 2002·27 cites·37 claims
- 1769US2025084164A1Compositions and methods for modulating lair signal transductionNEXTCURE INC·Filed 2024·Application pending·0 cites
- 1869US2011223188A1Targeted costimulatory polypeptides and methods of use to treat cancerLANGERMANN SOLOMON·Filed 2009·Application pending·0 cites
- 1968US2011195068A1Pd-1 antagonists and methods of use thereofLANGERMANN SOLOMON·Filed 2009·Application pending·0 cites
- 2066US2024400678A1Antibodies for siglec-15 and methods of use thereof to treat disuse osteoporosisNEXTCURE INC·Filed 2024·Application pending·0 cites
- 2159US2018079813A1Anti-h7cr antibodiesMEDIMMUNE LLC·Filed 2017·Application pending·0 cites
- 2257US2007166314A1EpA2 monoclonal antibodies and methods of use thereofMEDIMMUNE INC·Filed 2007·Application pending·0 cites
- 2355US2009162933A1Epha2 and hyperproliferative cell disordersKIENER PETER A·Filed 2008·Application pending·0 cites
- 2455US2013230514A1Compositions of pd-1 antagonists and methods of useLANGERMANN SOLOMON·Filed 2011·Application pending·0 cites
- 2554US9790277B2Anti-H7CR antibodiesAMPLIMMUNE INC·Filed 2013·Granted Oct 17, 2017·0 cites·34 claims
- 2654US2018066056A1Anti-h7cr antibodiesMEDIMMUNE LLC·Filed 2017·Application pending·0 cites
- 2754US2003099665A1Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infectionsFiled 2002·Application pending·0 cites
- 2854US2024352121A1Lair-1 agonistic antibodies and methods of use thereofNEXTCURE INC·Filed 2024·Application pending·0 cites
- 2953US12084495B2Compositions and methods for modulating LAIR signal transductionNEXTCURE INC·Filed 2017·Granted Sep 10, 2024·0 cites·12 claims
- 3053US2014227262A1PD-1 Antagonists and Methods for Treating Infectious DiseaseAMPLIMMUNE INC·Filed 2013·Application pending·0 cites
- 3151US12286478B2B7-H4 antibodies and methods of use thereofNEXTCURE INC·Filed 2019·Granted Apr 29, 2025·0 cites·16 claims
- 3251US2004028685A1EphA2 monoclonal antibodies and methods of use thereofFiled 2003·Application pending·0 cites
- 3350US2005196408A1Method of administering FimH protein as a vaccine for urinary tract infectionsMEDIMMUNE INC·Filed 2005·Application pending·0 cites
- 3449US2003138449A1Method of administering FimH protein as a vaccine for urinary tract infectionsMEDIMMUNE INC·Filed 2002·Application pending·0 cites
- 3549US2005175616A1PCDGF receptor antibodies and methods of use thereofFiled 2004·Application pending·0 cites
- 3649US2005059592A1EphA2 and hyperproliferative cell disordersFiled 2004·Application pending·0 cites
- 3747US2010278838A1Epha2 monoclonal antibodies and methods of use thereofMEDIMMUNE LLC·Filed 2010·Application pending·0 cites
- 3846US2023357384A1Compositions and methods for modulating flrt3 mediated signal transductionNEXTCURE INC·Filed 2021·Application pending·0 cites
- 3946US2005049176A1EphA2, hypoproliferative cell disorders and epithelial and endothelial reconstitutionFiled 2004·Application pending·0 cites
- 4043US2016130348A1Antibodies and other molecules that bind b7-h1 and pd-1MEDIMMUNE LLC·Filed 2015·Application pending·0 cites
- 4142US2003199071A1Mutant proteins, high potency inhibitory antibodies and fimch crystal structureFiled 2001·Application pending·0 cites
- 4239US2016146806A1Receptors for b7-h4AMPLIMMUNE INC·Filed 2014·Application pending·0 cites
- 4337US2013017199A1Simultaneous inhibition of pd-l1/pd-l2AMPLIMMUNE INC A CORP·Filed 2010·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →